Mizuho Securities USA LLC Has $75.84 Million Stake in Insulet Co. (NASDAQ:PODD)

Mizuho Securities USA LLC lifted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 5,928.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 325,821 shares of the medical instruments supplier’s stock after purchasing an additional 320,416 shares during the period. Mizuho Securities USA LLC owned 0.46% of Insulet worth $75,835,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. boosted its stake in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Insulet during the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC increased its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. increased its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the last quarter. Finally, CVA Family Office LLC boosted its holdings in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PODD. Canaccord Genuity Group lifted their price target on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. UBS Group upped their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Morgan Stanley raised their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. BTIG Research upped their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Citigroup upped their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Performance

Insulet stock opened at $260.12 on Friday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The stock has a fifty day moving average of $237.77 and a two-hundred day moving average of $207.47. The company has a market capitalization of $18.25 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 4.11 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.